International Forum of Allergy &Rhinology, Volume 16, Issue 9, Page 1012-1023, September 2026.ABSTRACT Background To systematically evaluate the local biomarkers correlated with olfactory dysfunction (OD) in chronic rhinosinusitis (CRS). Methods A systematic review was conducted in CINAHL, Cochrane Library, PubMed, and Scopus from inception to July 2025.
David Kayekjian +4 more
wiley +1 more source
Could Dupilumab Improve Sleep Quality in CRSwNP Patients: Myth or Reality? A Systematic Review. [PDF]
J Clin MedMoffa A +9 more
europepmc +1 more source
Real‐World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis
Clinical and Translational Allergy, Volume 16, Issue 9, September 2026.ABSTRACT Background Tralokinumab, an interleukin‐13 (IL‐13) monoclonal antibody, has shown clinical efficacy in randomized trials for moderate‐to‐severe atopic dermatitis (AD). This study aims to evaluate clinical and immunological outcome upon tralokinumab treatment in a real‐world cohort of patients with moderate‐to‐severe AD. Methods We recruited 81
Meslina Almaci +3 more
wiley +1 more source
Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center retrospective study. [PDF]
Front ImmunolWang Q, Yang G, Li Y, Xue J, Zhang L.
europepmc +1 more source
Inflammatory Factors in Allergic Rhinitis: A 20‐Year Bibliometric Mapping and Emerging Trends
Flavour and Fragrance Journal, Volume 41, Issue 5, Page 1076-1089, September 2026.This figure illustrates the bibliometric process and results of research on inflammatory factors of allergic rhinitis from 2004 to 2024 including data screening, global distribution, collaborative networks and the evolution of research hotspots. ABSTRACT Allergic rhinitis (AR) is driven by a network of inflammatory mediators released by mast cells ...
Shanshan Jing, Fengying Zhang, Qiqi Liu
wiley +1 more source
Successful Treatment of Severe Adult Linear IgA Dermatosis Using Dupilumab
JEADV Clinical Practice, Volume 5, Issue 3, Page 943-945, September 2026.ABSTRACT Linear IgA dermatosis (LAD) is a rare autoimmune subepidermal bullous dermatosis, characterised by the presence of erythematous vesiculobullous lesions arranged in rosettes or herpetiform clusters. The standard treatment involves the administration of dapsone, followed by sulfasalazine, and general corticosteroid therapy, often in combination ...
Célia Delesalle +7 more
wiley +1 more source
Severe non-atopic prurigo nodularis in an otherwise healthy elderly patient: rapid multidimensional response to dupilumab. [PDF]
Front PharmacolVentre A +3 more
europepmc +1 more source
HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis
JEADV Clinical Practice, Volume 5, Issue 3, Page 974-978, September 2026.ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal +2 more
wiley +1 more source
Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab. [PDF]
Clin Cosmet Investig DermatolYu L +5 more
europepmc +1 more source
Dupilumab for the treatment of pemphigoid gestationis in the setting of breastfeeding: a case report and review of the literature. [PDF]
Skin Health DisSoto-Canetti G, Navrazhina K, Talia J.
europepmc +1 more source